Projects
Scientific Projects
- CLARA: Center for Artificial Intelligence and Quantum Computing in System Brain Research, call: EU Teaming Call
- Successful in Phase 1
- Phase 2 deadline: March 7, 2024
- CLARA represents the very first interdisciplinary center of excellence focused on the next generation of artificial intelligence/ machine learning (AI/ML) applications and quantum-centric supercomputing tools to power interdisciplinary research programs aimed at solving the etiology of neurodegenerative diseases
- Distributed design of the Center consisted of partners acting in different fields of expertise will integrate diverse research knowledge and scientific excellence into a holistic translational research for brain health
- The CLARA team has developed a new machine-learning method to empower the computational design of biotherapeutics. The team is looking forward to extending this approach to biomolecules involved in neurodegeneration.
Consortium Partner Publications
- Detecting unrecognized cognitive impairment and dementia
In cooperation with Brain Watch Coalition Sandbox: An International Public-Private Coalition- Critical to the commercial success of all new interventions for chronic brain disorders
- Global healthcare systems struggle to identify cognitive, functional, and behavioral impairments that often lead to different types of dementia
- Obstacles include clinical workflow, personnel, ethical, financial, regulatory, or governance considerations
- AI/ML-powered clinical decision support applications offer promise but lack trust and confidence for:
- Healthcare: consumers, providers, and systems
- Global healthcare systems struggle to identify cognitive, functional, and behavioral impairments that often lead to different types of dementia
- The Sandbox: A Public-Private Collaboration to Provide Evidence to Drive Adoption
- Novel live-testing environment for AI/ML-powered clinical tools launching in six major U.S. healthcare systems serving over 15 million individuals
- 30 additional sites are currently under evaluation in North America, Europe and Asia
- Demonstration projects are currently in development in the U.S. with HHS, VA, DoD, and USDA
- Project funding is from life-science companies and philanthropy
- Critical to the commercial success of all new interventions for chronic brain disorders
- Assessing issue of drug responders/non-responders in clinical trials and drug repurposing
-
- The project aims to use computational and -omics methods to explore factors for failure or non- responsive in subsets of individuals who participated in unsuccessful Alzheimer’s intervention clinical trials.
- The goal is the identification of “optimal profile” within a subset of trial samples that positively responds to a specific intervention/asset.
- Current ongoing collaboration with UK based for profit FACULTY.AI
- Looking for partners & leader of this project